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Abstract
Background:  Angiogenic therapy with vascular endothelial growth factor (VEGF) has been
proposed as a treatment paradigm for patients suffering from an insufficiency of collateral vessels.
Diabetes is associated with increase in the production of VEGF and therefore additional VEGF may
not be beneficial. Accordingly, we sought to determine the efficacy of VEGF therapy to augment
collateral formation and tissue perfusion in a diabetic mouse ischemic hindlimb model.
Methods:  Diabetic and non-diabetic mice were studied in parallel for the efficacy of VEGF
administration. Diabetes was induced with streptozotocin. Hindlimb ischemia was produced by
severing the left iliac artery. An outlet tube from an osmotic infusion pump with placebo/ 500
micrograms of plasmid-DNA encoding VEGF was fenestrated and tunneled into the left quadriceps
muscle.
Results: VEGF induced more rapid and complete restoration of blood flow in normal mice.
However, in the setting of diabetes there was no difference between VEGF Vs. placebo in the rate
or adequacy of flow restoration. There was a significant increase in smooth muscle actin and
Factor-VIII antigen densities in diabetic animals and in animals which received VEGF.
Conclusions: Angiogenic therapy with VEGF in the setting of diabetes does not appear to have
the beneficial effects seen in the absence of diabetes.
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Introduction
Considerable variability exists between individuals in the
extent and functional utility of collateral vascular chan-
nels serving to effectively bypass obstructive atheroscle-
rotic lesions [1,2]. This variability has been demonstrated
in numerous prospective studies to be of primary impor-
tance in determining the amount and severity of ischemia
and necrosis which occurs subsequent to vessel occlusion.
The importance of angiogenesis and arteriogenesis in the
development of these collateral channels is now well
established [3]. Accordingly, angiogenic therapy with ang-
iogenic cytokines has been proposed as a paradigm to
treat all patients with an apparent inadequacy of collateral
vessels [4].
However, diabetes mellitus (DM) is associated with a
marked impairment in collateral formation and yet angio-
genesis is markedly increased in several vascular beds in
this disorder most notably in the retina [5,6]. Moreover,
there does not appear to be a defect in angiogenic growth
factor production in the setting of diabetes, but rather an
excess of growth factors production, such as vascular
endothelial growth factor (VEGF) which has been directly
linked to pathological angiogenesis in the diabetic patient
[7]. It has been suggested that impairment in collateral
formation in the diabetic patient is due to a defect in the
chemotaxis and in the signal transduction apparatus
mediating the response to VEGF in the monocyte [7,8].
Therefore, it is not clear why or if, additional VEGF would
be beneficial in restoring blood flow in the setting of dia-
betes. This question is of fundamental importance as the
diabetic patients represent a sizable fraction of those pres-
ently characterized as having inadequate collaterals [9]. In
this study we set out to determine if mice with diabetes
respond to angiogenic therapy with VEGF in the same
manner as non-diabetic mice.
Methods
Induction of Experimental Diabetes
All procedures and animal studies were approved by the
animal board and safety committee of the Faculty of Med-
icine, Technion – Israel Institute of Technology and com-
ply with all safety and regulatory guidelines.
Streptozotocin selectively destroys insulin-producing beta
islet cells of the pancreas providing a model of type I dia-
betes. Streptozotocin (Sigma, Rehovot, Israel) dissolved at
10 mg/ml in 0.1 M sodium citrate buffer (pH 5.5) was
injected intraperitonealy to 10 week-old male c57 mice
(35–40 gram) at a dose of 80 mg/kg. The mouse was con-
sidered diabetic and included in the study if the plasma
glucose levels at 72 hours was above 250 mg/dl in 2
repeated measurements, and remained elevated. An ele-
vated glucose level was found in 90% of mice injected
with streptozotocin.
Mouse hindlimb ischemia
Animal surgery: For surgical procedures and laser Doppler
analysis of hindlimb blood flow C57 mice were anesthe-
tized by intraperitoneal pentobarbital injection (160 mg/
kg). The surgical procedure was performed 4 weeks after
the induction of DM and was done under a microscope.
Skin incisions were performed at the groin of the left
hindlimb overlying the iliac artery, and carried out down-
ward. The iliac artery was then ligated proximally and dis-
tally with 4-0 silk ligatures, and excised. All accessory
arteries were ligated and cut. Prior to closure, a 200 µl
osmotic infusion pump (Alzet osmotic pumps, Durect
corporation, Cupertino, CA, USA) containing a 5% glu-
cose solution with or without 500 micrograms of plasmid
DNA encoding for VEGF was implanted intra-abdomi-
nally with an outlet tube from the pump fenestrated and
tunneled into the left quadriceps muscle. We have previ-
ously performed a dose response curve (0–500 micro-
grams of VEGF DNA) using the hindlimb ischemia model
described above and the VEGF DNA vector described
below and have determined that the maximal effect is
seen at a dose of 500 microgram of the plasmid DNA. The
pump rate has been documented to be 1 µl per hour,
which given a 200 µl reservoir would allow continuous
perimuscular pumping for approximately seven days. The
overlying skin was then closed with continuous surgical
sutures using 3-0 silk ligatures.
Study groups
In this study there were 4 groups: Normal-VEGF, Normal-
placebo, DM-VEGF and DM-placebo. In each group 18–
21 mice were included. The operation as well as all blood
flow measurements and blood vessel density calculations
were done without knowledge of the treatment given.
Mole rat VEGF
The coding sequence for VEGF used in this study was
cloned from the Israeli mole rat (Spalax ehrenbergi), which
is indigenous only to Egypt, Israel, and Syria [10]. The
coding sequence of mole rat VEGF was previously
described [11]. The entire approximately 1 kb of 5' UTR of
mole rat VEGF mRNA was cloned by RT-PCR and juxta-
posed to the mole rat VEGF165 amino acid isoform
(VEGF-165) coding sequence. The sequence homology of
mole rat, rat, mouse and human VEGF is over 90% in the
coding region [11].
Vector/regulatory sequences used
The isolated Spalax cDNA for VEGF-165 with its 1 kb of 5'
UTR were cloned into pTRE (Clontech, Palo Alto, CA,
USA) and is hereafter referred to as the VEGF vector. This
vector utilized the 763 bp cytomegalovirus promoter /
enhancer element to drive VEGF transcription and down-
stream of the VEGF cDNA sequences there was an intron
and a polyadenylation signal sequence derived from SVCardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/18
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40. Vector was purified using Qiagen columns (Hilden,
Germany) and resuspended in a 5% glucose solution at a
concentration of 2.5 µg/microliter. Placebo animals
received only 5% glucose in the osmotic pump. We also
examined in the past, a second "placebo" group which
included only the backbone pTRE vector without the
VEGF gene, which resulted in similar results as the pla-
cebo (data not reported here).
Monitoring hindlimb blood flow
Ischemic (left) / normal (right) limb blood flow ratio was
measured using a laser Doppler blood flow meter (Per-
imed-4000, Jarfalla, Sweden). Measurements were per-
formed on a multichannel laser-Doppler flowmeter
(PeriFlux 4001 Master; Perimed AB, Jarfalla, Sweden) at a
wavelength of 780 nm, using two probes (PF 415:42) with
fiber separation of 0.5 mm. The laser Doppler uses a 12-
mW helium neon laser beam that sequentially scans a
defined surface area. A photodiode in the scanner collects
the backscattered light emitted by the laser and the shift in
the frequency of the incident light is transformed into
voltage variations in the range of 0–10 V which is directly
related to blood flow distribution. Previous studies have
validated that Doppler flow velocity correlates with capil-
lary density in the ischemic limb [12]. For measurements
of capillary perfusion, the probes were placed perpendic-
ular to the foot. Recordings were obtained continuously
for 2 minutes each, at 5 different points over the mouse
foot. The capillary blood flow was calculated, using
Perisoft software (version-5.10C2), by multiplying the
concentration of moving blood cells (concentration
units) by mean velocity of the cells (velocity units) and
expressed as perfusion units [13]. Hindlimb blood flow
was monitored every week until reaching a plateau or a
normal value.
Immunohistochemistry
Animals were sacrificed at predetermined time points
after surgery by an overdose of sodium pentobarbital. For
each limb 2 sections were selected for analysis, a proximal
area (mid quadriceps muscle) and a distal area (mid gas-
trocnemius muscle), presented hereafter as proximal and
distal.
For immunohistochemical analysis, five-micrometer
thick sections were prepared from paraffin embedded tis-
sue samples of the limbs. Sections were cut with the mus-
cle fibers oriented transversely. Identification of
endothelial cells was performed by immunostaining for
Factor VIII related antigen using a polyclonal anti-factor
VIII antiserum at a 1/20 dilution (Zymed, San Francisco,
CA). Immunostaining for smooth muscle actin using a
mouse monoclonal antibody at 1/100 dilution (Zymed)
was used to identify smooth muscle cells. Immunohisto-
chemistry was performed on an automated system (Vent-
anu Medical Systems, Tucson, Az). Capillary density in
both ischemic and non-ischemic limbs was determined
by counting endothelial cells positively stained with Fac-
tor VIII under light microscopy. Analysis of smooth mus-
cle cells was performed in order to differentiate arterioles
from capillaries or venules. The microvessel density
(obtained by either Factor VIII or smooth muscle actin
staining) was computed using a computerized image
analysis system composed of a trichip RGB video-camera
(Sony, Japan), installed on a light microscope (Zeiss, Ger-
many) and attached to personal computer, equipped with
a frame grabber. Histological images were captured, digi-
tized and displayed on a high-resolution monitor. Five
microscopic fields were analyzed, using a medium sized
magnifying lens (× 200) and were loaded on a 760 × 570
pixels buffer area. The microvessel density parameter was
measured using the Image Pro-Plus 4 image analysis soft-
ware (Media Cybernetics, Silver Spring, MD, USA). Thirty
randomly chosen high-power fields in two different light
microscopic sections from the 4 sites in each limb of each
animal were counted and blood vessel density expressed
as number of blood vessels/mm2. A ratio in each level,
between the legs was then calculated.
Blood flow ratio with time Figure 1
Blood flow ratio with time. Time dependent increase in 
blood flow in normal and diabetic mice with and without 
VEGF. Each group at each time point contains 18–21 animals. 
The Normal VEGF is statistically significant by 1-week as 
compared to all other treatment arms. There is no statisti-
cally significant difference between all other treatment 
groups.Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/18
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Statistical Analysis
Multiple parametric groups were compared using the one-
way ANOVA test followed by the Bonferroni post-hoc test.
P values of 0.05 or less were considered to be statistically
significant
Results
Restoration of Flow
Pre-operatively the ratio of blood flow between the two
hindlimbs for all animals used in this study was 1.0.
Immediately after the operation in all animals the oper-
ated limb developed a blue-gray color and the ratio of the
blood flow between the ischemic and normal limb was
less than 0.2 (figure 1).
A more complete and rapid restoration of blood flow was
observed in the normal-VEGF treated mice as compared to
the other three study groups (normal placebo, Diabetic-
VEGF and Diabetic placebo). In normal mice receiving
VEGF there was a statistically significant improvement in
flow that was evident as early as 1-week after beginning
infusion with VEGF as compared to the other three groups
(p < 0.05). There was no difference in the rate of restora-
tion of flow between the normal placebo, diabetic pla-
cebo and diabetic VEGF groups. Restoration of flow in all
groups reached a plateau by 3 weeks after which no fur-
ther differences in the ratio of the ischemic to non
ischemic limb was noted (Figure 1). This 21-day time
point was therefore indicative of the completeness of res-
toration of blood flow. Normal mice treated with VEGF
not only returned flow to normal at this time point but
even surpassed that in the normal limb at the 3-week time
point (ratio greater than 1.0). However, in all three other
groups the ratio never returned to 1.0 but rather plateaued
only to a level of 0.8–0.9 at 3-weeks.
Vessel Density Ratio
Immunohistochemical methods were used to identify the
Factor VIII related antigen present on endothelial cells
and thus representing capillaries as well as arterioles, and
to identify smooth muscle actin which is found only on
non-capillary vessels. Angiogenesis, or new blood vessel
formation occurs at the level of the capillary. These new
vessels as well as other preexisting capillaries may mature
into larger vessels by the process of arteriogenesis. An
increase in the number of endothelial cells was therefore
interpreted as being indicative of angiogenesis while an
increase in smooth muscle cells was interpreted as being
indicative of arteriogenesis. There was a significant
increase in factor VIII and actin staining in DM animals
who did receive VEGF compared to DM animals who did
not receive VEGF. VEGF in the setting of diabetes resulted
in an increase in vessel density distally (Figure 2, Factor
VIII staining) and an increase in smooth muscle actin
staining (Figure 3) proximally and distally in comparison
Ratio of factor VIII positive cells in the ischemic to  nonischemic limb in the proximal and distal limb segments Figure 2
Ratio of factor VIII positive cells in the ischemic to 
nonischemic limb in the proximal and distal limb segments. 
Ratios (Proximal; Distal) Normal VEGF (1.4; 1.6), DM VEGF 
(3.2; 1.9), DM placebo (3.4; 0.9). Each group contains 4 or 5 
animals. [* – p < 0.01].
Ratio of smooth muscle actin positive cells in the ischemic to  nonischemic limb in the proximal and distal limb segments Figure 3
Ratio of smooth muscle actin positive cells in the ischemic to 
nonischemic limb in the proximal and distal limb segments. 
Each group contains 4 or 5 animals. Ratio and P Values: Prox-
imal: VEGF arm (1.8) Vs. Placebo (1.5) p < 0.05, Vs both DM 
arms p < 0.001, Normal placebo Vs. both DM arms p < 
0.001, DM VEGF (4.5) Vs DM-Placebo (3.6) p < 0.05. Distal: 
VEGF arm (1.0) Vs. Placebo (1.1) p = NS, Vs DM-VEGF p < 
0.001, Vs. DM-Placebo p < 0.01, DM VEGF (14.6) Vs DM-Pla-
cebo (1.7) p < 0.01.Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/18
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to diabetic animals that did not receive VEGF. The ratio
for factor VIII for normal-placebo could not be calculated
due to excessive necrosis.
Discussion
We have previously demonstrated that angiogenic therapy
with VEGF results in a significant improvement in the rate
and completeness of restoring blood flow to an ischemic
limb in normal animals [10]. The chief objective of the
present study was to determine whether VEGF could
improve blood flow to an ischemic limb in the setting of
diabetes. We found that the answer to this question is no.
We therefore sought to determine whether this failure of
VEGF to stimulate blood flow in a diabetic animal was
due to (1) an impairment in the ability to deliver VEGF to
the diabetic ischemic limb or (2) an impairment in the
ability of VEGF to stimulate endothelial growth (angio-
genesis) and/or new smooth muscles (arteriogenesis).
Our data clearly demonstrates that neither of these poten-
tial explanations can explain why VEGF fails to increase
blood flow in the setting of diabetes. Despite the apparent
benefit from VEGF as evidenced from an increase in factor
VIII and smooth muscle actin in the DM animals who
received VEGF as compared to those DM animals who did
not receive VEGF there was no benefit in terms of blood
flow.
Our findings stand in conflict with those previously
described by Rivard et al [14] who reported that ang-
iogenic therapy with VEGF results in an amelioration of
blood flow to diabetic animals with an ischemic limb.
Rivard et al attributed the success of providing additional
VEGF in the setting of diabetes to an impairment in VEGF
production in the diabetic ischemic limb. However the
findings reported by Rivard et al are not consistent with a
growing body of literature demonstrating that there is an
increased production of VEGF in the setting of diabetes
[15]. Cooper et al [16] have shown in diabetic rats an
increase in VEGF production as well as an upregulation of
VEGF receptors. Hyperglycemia results in a dramatic
upregulation of VEGF expression in a variety of cell types
[17,18], which is due to a transcriptional activation of the
VEGF gene (Levy et al, unpublished observations). This
increase in VEGF production in the setting of diabetes is
consistent with an increase in angiogenesis in diabetic
animals and humans at sites in which ischemia is present
such as in the retina.
Since there does not appear to be a defect in angiogenesis
or arteriogenesis in the setting of increased VEGF in dia-
betic animals but there is an impairment in the restora-
tion of blood flow we need to consider other pathogenic
mechanisms which do not involve a deficiency in VEGF
production [19]. One of the key features involved in the
maturation of blood vessels into larger conduits is a
remodeling of the vessel by monocyte/macrophages. The
ability of monocytes to migrate towards a gradient of
VEGF is severely impaired in diabetic individuals [7]. A
second defect present in diabetic individuals that could
result in a decreased blood flow despite an adequate
number of blood vessels is an impairment in endothelial
dependent relaxation [5,9]. Recently, Tepper et al [20]
reported that circulating endothelial progenitor cells from
type II diabetes patients had decreased adherence to
human umbilical vein endothelial cells activated by
tumor necrosis factor-α (TNF-α) and were less likely to
participate in tubule formation compared with controls.
Further research on the interaction between DM and ang-
iogenesis is warranted.
Conclusions
In diabetes, the VEGF dependent angiogenic pathway may
be activated to maximum, therefore giving more of this
factor may not further augment blood flow.
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